Navigation Links
Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
Date:7/11/2013

CINCINNATIA recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

The protein, called "Tissue Factor," is present in various tissuesfor example, walls of blood vessels. Earlier studies suggested that alternatively spliced Tissue Factor (asTF) may contribute to cancer growth, but the molecular events leading to this were previously unknown.

New research conducted through an international collaboration between the labs of Vladimir Bogdanov, PhD, of the University of Cincinnati Cancer Institute, and Henri Versteeg, PhD, of the Einthoven Laboratory for Experimental Vascular Medicine at the Leiden University Medical Center in Leiden, the Netherlands, articulates how asTF fuels growth and metastasis of solid cancers.

Using preclinical animal models, Bogdanov and Versteeg's teams obtained the first scientifically validated evidence that asTF promotes the spread of pancreatic cancer and promotes primary growth of breast cancer tumors.

"We have demonstrated that targeting asTF with a novel monoclonal antibodydeveloped based on our 10 years of studying asTFalso stops the growth of breast cancer in an animal model, giving us a promising new target to fight certain forms of breast cancer," says Bogdanov, who originally described asTF in 2003. UC filed a patent for this technology in January 2013.

Bogdanov and Versteeg presented their findings at the XXIV Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, the Netherlands (held June 29-July 4, 2013).

"Many molecules on the surface of cellsincluding integrinsare important for the function of both normal and cancerous cells, so targeting integrins for stopping the growth of cancer is not a promising strategy. What is unique about asTF is that it binds to integrins on vessel-forming cells, activating them. We've shown that certain cancer cells share those same qualities, so if you target asTFwhich is elevated in cancerthere is significant potential to spare the 'good' parts of the cellular system while removing the 'bad' cancer-specific protein from the game," explains Bogdanov.

"Many routine therapies such as chemotherapy or radiation may not always be efficient. Targeting asTF in tumors using our monoclonal antibody may form a potent additional anticancer strategy in combination with conventional avenues", says Versteeg.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. Mechanism found connecting metastatic breast cancer and arthritis
2. Cancerous tumors deliver pro-metastatic information in secreted vesicles
3. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
4. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Modulating the immune system to combat metastatic cancer
8. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
9. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
10. Commonly used diabetes drug may help to prevent primary liver cancer
11. Biology professor secures grant to save West Virginias primary natural history collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2019)... ... July 26, 2019 , ... Worldwide Business with ... Technologies CEO Phil Deschamps to discuss their potential new treatment option to manage ... a neurotech company in the medical device industry that's focused on neurological wellness. ...
(Date:7/23/2019)... ... July 23, 2019 , ... My Gene ... today announced that the company has expanded its database of genetic resources to ... (FH), and Parkinson’s disease. , The expanded content comes following 23andMe’s June 2019 ...
(Date:7/21/2019)... ... July 20, 2019 , ... ... Technologies ( http://www.fluidimaging.com ) announced today the release of the biggest software ... imaging and characterization platform will provide a significant increase in productivity for ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, Inc. ... agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC ... retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal diseases. ...
(Date:6/12/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... June ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... partnership agreement with Shanghai Zillion has been signed. The agreement will grant exclusive ...
(Date:6/11/2019)... ... 2019 , ... Advancements with Ted Danson will focus on ... 4Q/2019. Check your local listings for more information. , Advancements will explore Bio-ITech ... facilitates laboratories to improve efficiency and quality of research by providing comprehensive and ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... Carilion Clinic, a national leader in opioid treatment, announced today they are partnering ... , Mytonomy recently deployed its virtual care platform at the Mayo Clinic ...
Breaking Biology Technology: